anticipated dip this week due to the Labor Day holiday. Sales were down 12% from last week's numbers according to industry source IMS Health. While seeing sales dip is never a positive, the news was essentially expected and the stock price did not carry an overwhelming
range of antiretroviral therapies upon which around 40% of HIV/AIDS patients in developing countries depend. According to IMS Health , Mylan currently has 294 abbreviated new drug applications pending for FDA approval which represent $105.7 billion in
By Spencer Osborne : Orexigen (NASDAQ: OREX ) received FDA approval for its anti-obesity drug Contrave on September 10, 2014. This is now the third "new" entrant into the space. Belviq, from Arena Pharmaceuticals (NASDAQ: ARNA ) and Qsymia from Vivus (NASDAQ: VVUS ) have already been on the market
mg/5 mL. The product is the therapeutic equivalent of Lehigh Valley Technologies' Oxycodone Hydrochloride Oral Solution USP, 100 mg/5 mL. According the IMS Health, the U.S. wholesale market is ~$43M per year. Post your comment!
in escrow pending the satisfaction of certain conditions. Aspen will supply Arixtra and its generic to Mylan. According to IMS Health, U.S. sales of branded Arixtra were $18.8M for the 12-month period ending June 30, 2014. Generic Arixtra sales
anti-obesity pill Belviq from Arena Pharmaceuticals (NASDAQ: ARNA ) were up modestly this past week, according to industry tracker IMS Health. Total sales were a bit over 11,400 scripts, and the percentage gain from last week was about 1.4%. New scripts
By Spencer Osborne : With an all important FDA approval decision just a week away on NB32 (known as Contrave), Orexigen (NASDAQ: OREX ) has announced this week that the drug has just received a new patent with regard to insulin resistance. NB32 has demonstrated very positive results for diabetes ...
its ANDA so it has 180 days of marketing exclusivity before other generic makers' offerings are cleared for sale. According to IMS Health, Baraclude generated ~$330M in sales in the 12-month period ended June 2014. Post your comment!
numbers last week. For the first time, sales of Belviq eclipsed the 11,000 level according to industry tracker IMS Health (NYSE: IMS ). The reason that the 11,000 level is critical is that it has represented a sales ceiling for another weight
it expects to be eligible for 180 days' market exclusivity (although this is based on the "first to file"). According to IMS Health, Copaxone generated ~$412M in U.S. sales over the 12-month period ending June 30, 2014. Post your comment!